Valuation: CorMedix Inc.

Market Cap 415M 370M 341M 309M 586M 38.87B 600M 4.07B 1.62B 20.81B 1.56B 1.52B 65.54B P/E 2026 *
10.8x
P/E 2027 * 399x
Enterprise Value 415M 370M 341M 309M 586M 38.87B 600M 4.07B 1.62B 20.81B 1.56B 1.52B 65.54B EV / Sales 2026 *
1.23x
EV / Sales 2027 * 1.47x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day+2.82%
1 week+1.48%
Current month-3.95%
1 month-25.88%
3 months-27.36%
6 months-28.59%
Current year-52.97%
1 week 5.1
Extreme 5.1
5.79
1 month 5.1
Extreme 5.1
8.35
Current year 5.1
Extreme 5.1
12.29
1 year 5.1
Extreme 5.1
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Exercice

Director

97,818 0.1255%
29/8/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/8/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+2.82%+1.48%-50.63%+81.13% 415M
+4.28%+0.07%+46.07%+138.78% 1,206B
+2.13%+4.27%+49.73%+91.36% 665B
+0.68%+1.54%+34.10%+112.47% 515B
+2.77%-0.57%+49.44%+68.42% 381B
+1.38%+0.27%+71.48%+45.30% 362B
+0.29%-0.24%+30.84%+57.23% 307B
+0.98%+0.76%+9.04%+38.31% 289B
+1.04%-0.05%+43.74%+76.18% 249B
+1.46%-0.59%+43.31%+125.82% 207B
Average +1.46%-2.04%+32.71%+83.50% 418.02B
Weighted average by Cap. +2.13%-1.96%+43.72%+96.20%

Financials

2026 *2027 *
Net sales 336M 300M 276M 251M 475M 31.53B 487M 3.31B 1.32B 16.88B 1.26B 1.24B 53.17B 281M 251M 231M 210M 398M 26.38B 408M 2.77B 1.1B 14.13B 1.06B 1.03B 44.49B
Net income 45.39M 40.52M 37.28M 33.84M 64.13M 4.25B 65.72M 446M 178M 2.28B 170M 167M 7.17B 2.11M 1.88M 1.73M 1.57M 2.98M 198M 3.05M 20.72M 8.26M 106M 7.92M 7.75M 333M
Net Debt - -
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
10/11/26 US$5.470 +2.82% 2,323,834
06/11/26 US$5.320 +1.72% 1,616,987
05/11/26 US$5.230 -7.60% 1,834,485
04/11/26 US$5.660 +1.80% 1,492,241
03/11/26 US$5.560 +3.15% 2,459,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.320USD
Average target price
15.20USD
Spread / Average Target
+185.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CorMedix Inc.
  1. Stock Market
  2. Stocks
  3. CRMD Stock